Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Mallinckrodt
Merck
Boehringer Ingelheim
AstraZeneca

Last Updated: June 27, 2022

QUDEXY XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Qudexy Xr patents expire, and what generic alternatives are available?

Qudexy Xr is a drug marketed by Upsher Smith Labs and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has eleven patent family members in six countries.

The generic ingredient in QUDEXY XR is topiramate. There are twenty-six drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the topiramate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Qudexy Xr

A generic version of QUDEXY XR was approved as topiramate by ACCORD HLTHCARE on March 27th, 2009.

  Try it Free

Paragraph IV (Patent) Challenges for QUDEXY XR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
QUDEXY XR Extended-release Capsules topiramate 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg 205122 1 2015-12-24

US Patents and Regulatory Information for QUDEXY XR

QUDEXY XR is protected by five US patents.

Patents protecting QUDEXY XR

Extended-release topiramate capsules
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEIZURES

Extended-release topiramate capsules
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Extended-release topiramate capsules
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Extended-release topiramate capsules
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Extended-release topiramate capsules
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher Smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-001 Mar 11, 2014 AB2 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Upsher Smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-004 Mar 11, 2014 AB2 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-005 Mar 11, 2014 AB2 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-002 Mar 11, 2014 AB2 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-001 Mar 11, 2014 AB2 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upsher Smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-003 Mar 11, 2014 AB2 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for QUDEXY XR

See the table below for patents covering QUDEXY XR around the world.

Country Patent Number Title Estimated Expiration
Canada 2905011 CAPSULE DE TOPIRAMATE A LIBERATION LENTE (EXTENDED-RELEASE TOPIRAMATE CAPSULES) See Plans and Pricing
South Korea 20160124930 서방성 토피라메이트 캡슐 (EXTENDED-RELEASE TOPIRAMATE CAPSULES) See Plans and Pricing
Israel 250373 See Plans and Pricing
South Korea 20150132838 서방성 토피라메이트 캡슐 (EXTENDED-RELEASE TOPIRAMATE CAPSULES) See Plans and Pricing
Brazil 112015022434 cápsulas de topiramato de liberação estendida See Plans and Pricing
European Patent Office 2968177 CAPSULE DE TOPIRAMATE À LIBÉRATION LENTE (EXTENDED-RELEASE TOPIRAMATE CAPSULES) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for QUDEXY XR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0138441 SPC/GB95/028 United Kingdom See Plans and Pricing PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Moodys
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.